Trial
NCT02009761
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Purpura, Thrombocytopenic, Idiopathic
Intervention
BI 655064
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-15